Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00628420 · ClinicalTrials.gov registry record · Phase 1
Safety Study of ACP-104: To Demonstrate the Safety, Tolerability, and Pharmacokinetics
A Phase 1 study, sponsored by University of Texas Southwestern Medical Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 45
- Enrollment target
NCT00628420 is a Phase 1 study that has completed, run by University of Texas Southwestern Medical Center. The registered enrollment target is 45 participants.
The verdict
NCT00628420, a Phase 1 study, has completed, sponsored by University of Texas Southwestern Medical Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 45 participants
- Enrollment target
Study Summary
To determine the safety and tolerability of ACP-104 after oral administration of single doses in comparison with placebo to schizophrenia or other psychotic disorders.
Interventions
- DRUG Placebo
- DRUG ACP-104
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 45 participants |
| Start Date | 2005-01 |
| Est. Completion | 2007-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00628420
The ClinicalTrials.gov registry entry for NCT00628420 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 45 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Texas Southwestern Medical Center, which has 837 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00628420 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00628420 about?
NCT00628420 is a clinical study titled "Safety Study of ACP-104: To Demonstrate the Safety, Tolerability, and Pharmacokinetics". To determine the safety and tolerability of ACP-104 after oral administration of single doses in comparison with placebo to schizophrenia or other psychotic disorders.
What is the current status of trial NCT00628420?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 45 participants. The study started on 2005-01. Estimated completion is 2007-10.
What interventions are being tested in trial NCT00628420?
The interventions under investigation include: Placebo (DRUG), ACP-104 (DRUG).
Who is sponsoring clinical trial NCT00628420?
This trial is sponsored by University of Texas Southwestern Medical Center, which has 837 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.